CHEST IPF 2016

Care of patients with IPF has been transformed since the 2014 FDA approval of pirfenidone and nintedanib for the treatment of patients with IPF. Providers considering these treatments for their patients face decisions of which protocol is best for an individual patient, when to start, switch or combine treatments, and how to manage side effects and dosing. Explore real-world issues of treating patients with IPF. Presented in Los Angeles, California - October 2016.

Faculty: Paul W. Noble, MD and Jonathan Goldin, PhD, MD

 

Download [pptx ยป 13MB]

Access other Therapeutic Areas: